Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L. McQuade, Michael A. Davies, Lauren E. Haydu et al.|The Lancet Oncology|2018Cited by 658
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Caroline Robert, Georgina V. Long et al.|European Journal of Cancer|2017Cited by 171
COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanomaAxel Hauschild, John M. Kirkwood, Mario Santinami et al.|Annals of Oncology|2017Cited by 7